Organigram Global (OGI) Stock Price, News & Analysis

Company Overview

Organigram Global Inc. (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts. Organigram distributes under a variety of brands, including Monjour, Edison and First Growth, targeting diverse consumer segments from value-focused to premium. Its cultivation methods combine indoor and greenhouse systems with automated processes designed to ensure product consistency, safety and quality.

Organigram serves markets across Canada and has established partnerships to access select international markets in jurisdictions that recognize Canadian GMP certification. The company’s leadership team is led by Chief Executive Officer Greg Engel, who has guided Organigram through its public listings on the Toronto Stock Exchange and the Nasdaq in 2020. Under his management, Organigram has focused on innovation in product formats, efficiency in cultivation, and strategic brand development to navigate the evolving regulatory landscape.

Key Stats

• Today's Range: $1.38 to $1.43
• 50-Day Range: $1.25 to $1.59
• 52-Week Range: $1.10 to $2.24
• Volume: 787,865 shs
• Average Volume: 822,881 shs
• Market Capitalization: $195.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Organigram Global Stock Analysis - MarketRank™

Organigram Global scored higher than 18% of companies evaluated by MarketBeat, and ranked 784th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Organigram Global has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Organigram Global has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: -60.00%

Earnings Growth

Earnings for Organigram Global are expected to decrease by -60.00% in the coming year, from $0.10 to $0.04 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Organigram Global is 9.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.48.

Price to Earnings Ratio vs. Sector

The P/E ratio of Organigram Global is 9.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.30.

Price to Book Value per Share Ratio

Organigram Global has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OGI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Organigram Global does not currently pay a dividend.

Dividend Growth

Organigram Global does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 5 news articles for Organigram Global this week, compared to 2 articles on an average week.

Search Interest

6 people have searched for OGI on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

8 people have added Organigram Global to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Organigram Global insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.09% of the stock of Organigram Global is held by insiders.

Percentage Held by Institutions

34.63% of the stock of Organigram Global is held by institutions.

OGI Stock Analysis - Frequently Asked Questions

How have OGI shares performed this year?

Organigram Global's stock was trading at $1.68 at the beginning of 2026. Since then, OGI shares have decreased by 17.3% and is now trading at $1.39.

How were Organigram Global's earnings last quarter?

Organigram Global Inc. (NASDAQ:OGI) posted its quarterly earnings data on Tuesday, February, 10th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.01. The firm earned $46.27 million during the quarter, compared to analyst estimates of $73.38 million. Organigram Global had a net margin of 6.03% and a negative trailing twelve-month return on equity of 15.41%.
Read the conference call transcript.

When did Organigram Global's stock split?

Shares of Organigram Global reverse split before market open on Friday, July 7th 2023.The 1-4 reverse split was announced on Friday, July 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Who are Organigram Global's major shareholders?

Organigram Global's top institutional shareholders include AdvisorShares Investments LLC (0.69%), Formidable Asset Management LLC (0.11%) and Leonteq Securities AG (0.10%).

How do I buy shares of Organigram Global?

Shares of OGI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Organigram Global own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Organigram Global investors own include i3 Verticals (IIIV), Ford Motor (F), Lucid Group (LCID), Trade Desk (TTD), Finance of America Companies (FOA), NVIDIA (NVDA) and

Company Calendar

• Last Earnings: 2/10/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/11/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OGI
• CIK: 1620737
• Web: www.organigram.ca
• Phone: (844) 644-4726
• Fax: N/A
• Employees: 1,139
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): $0.14
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.70 million
• Net Margins: 6.03%
• Pretax Margin: 1.59%
• Return on Equity: -15.41%
• Return on Assets: -10.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.73
• Quick Ratio: 1.32

Sales & Book Value

• Annual Sales: $185.07 million
• Price / Sales: 1.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.86 per share
• Price / Book: 0.75

Miscellaneous

• Outstanding Shares: 140,770,000
• Free Float: 140,641,000
• Market Cap: $195.67 million
• Optionable: Optionable
• Beta: 1.50